NCT03748745已完成1 期
A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
The purpose of this study is to evaluate the drug-drug interaction of SH229 tablets and Daclatasvir dihydrochloride tablets. The study also evaluates the pharmacokinetics and tolerability of co-administration of SH229 tablets and Daclatasvir dihydrochloride tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.
详细描述
A total of 28 evaluable healthy subjects will be enrolled in this study. The dose of SH229 is 600 mg. The dose of Daclatasvir dihydrochloride is 60 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent form before the study and fully understand the study content, process and possible adverse reactions;
- •Be able to complete the study as required by the protocol;
- •Subjects (including their partners) who are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose. See the appendix for specific contraceptive measures;
- •Male subjects aged 18-45 (including 18 and 45 years old);
- •Male subjects who weigh no less than 50 kg and have a body mass index between 18 and 28 kg / m2 (including the threshold). Body mass index (BMI) = weight (kg) / height2 (m2);
- •Physical examination and vital signs normal, or the abnormal signs have no clinical significance.
排除标准
- •Smoke more than 5 cigarettes per day within three months prior to study;
- •Subjects who are allergic to the study drugs or prone to allergies (Multiple drug and food allergies);
- •Subjects with history of drug and/or alcohol abuse (14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);
- •Subjects with history of blood donation or massive blood loss (> 450 mL) within three months prior to screening;
- •Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption;
- •Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
- •Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
- •Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;
- •Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the absorption, distribution, metabolism and excretion of the study drug within 2 weeks prior to screening;
- •Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone;
- •Subjects with major changes in diet or exercise habits recently;
- •Use of study drugs or participation in other clinical trials within three months prior to dosing;
- •Subjects who have ECG abnormalities with clinical significance;
- •Subjects who have abnormalities with clinical significant in clinical laboratory tests or other clinical findings that indicate clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric or cardiovascular diseases);
- •Subjects with viral hepatitis (including hepatitis B and hepatitis C), AIDS antibody and/or antibody screening positive for Treponema pallidum;
- •Subjects with acute disease or concomitant use of drugs from screening stage to dosing;
- •Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing;
- •Use of products containing alcohol within 24 hours prior to dosing;
- •Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years;
- •Subjects with any other reasons that investigator considers to be unsuitable for the study.
研究组 & 干预措施
Cohort A
Experimental
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
干预措施: SH229 (Drug)
Cohort A
Experimental
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
干预措施: Daclatasvir dihydrochloride (Drug)
Cohort B
Experimental
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
干预措施: SH229 (Drug)
Cohort B
Experimental
SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
干预措施: Daclatasvir dihydrochloride (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Up to 1 month after last dose
Cohort A and Cohort B \[Safety and tolerability\]
次要结局
- Tmax, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- Cmax, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- t1/2, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- AUC0-24, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- AUC0-72, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- AUC0-∞, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- CL/F ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- DF(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
- Cmin, ss(Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusHepatitis C VirusNCT01628692Bristol-Myers Squibb230
已完成
2 期
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)Hepatitis C InfectionNCT01017575Bristol-Myers Squibb55
已完成
1 期
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy SubjectsChronic Hepatitis BNCT03662568Sunshine Lake Pharma Co., Ltd.56
已完成
1 期
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy SubjectsChronic Hepatitis CNCT04232514Sunshine Lake Pharma Co., Ltd.28
已完成
2 期
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve PatientsHepatitis C VirusNCT01125189Bristol-Myers Squibb558